Switch theme
Sign up to access all valuation multiples
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
2002
33
LTM Revenue $0.6M
LTM EBITDA n/a
$173M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cardiff Oncology has a last 12-month revenue of $0.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cardiff Oncology achieved revenue of $0.7M and an EBITDA of -$48.2M.
Cardiff Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cardiff Oncology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $0.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$45.0M | -$48.2M | XXX | XXX | XXX |
| EBITDA Margin | -9224% | -7064% | XXX | XXX | XXX |
| Net Profit | -$38.7M | -$41.4M | XXX | XXX | XXX |
| Net Margin | -7931% | -6067% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Cardiff Oncology's stock price is $4.
Cardiff Oncology has current market cap of $263M, and EV of $173M.
See Cardiff Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $173M | $263M | XXX | XXX | XXX | XXX | $-0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Cardiff Oncology has market cap of $263M and EV of $173M.
Cardiff Oncology's trades at 281.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cardiff Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cardiff Oncology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $173M | XXX | XXX | XXX |
| EV/Revenue | 252.6x | XXX | XXX | XXX |
| EV/EBITDA | -3.6x | XXX | XXX | XXX |
| P/E | -5.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCardiff Oncology's NTM/LTM revenue growth is -53%
Cardiff Oncology's revenue per employee for the last fiscal year averaged $21K, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Cardiff Oncology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cardiff Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cardiff Oncology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7064% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -7117% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $21K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1828% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5396% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 7223% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cardiff Oncology acquired XXX companies to date.
Last acquisition by Cardiff Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Cardiff Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cardiff Oncology founded? | Cardiff Oncology was founded in 2002. |
| Where is Cardiff Oncology headquartered? | Cardiff Oncology is headquartered in United States of America. |
| How many employees does Cardiff Oncology have? | As of today, Cardiff Oncology has 33 employees. |
| Who is the CEO of Cardiff Oncology? | Cardiff Oncology's CEO is Dr. Mark Erlander, PhD. |
| Is Cardiff Oncology publicy listed? | Yes, Cardiff Oncology is a public company listed on NAS. |
| What is the stock symbol of Cardiff Oncology? | Cardiff Oncology trades under CRDF ticker. |
| When did Cardiff Oncology go public? | Cardiff Oncology went public in 1997. |
| Who are competitors of Cardiff Oncology? | Similar companies to Cardiff Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cardiff Oncology? | Cardiff Oncology's current market cap is $263M |
| What is the current revenue of Cardiff Oncology? | Cardiff Oncology's last 12-month revenue is $0.6M. |
| What is the current EV/Revenue multiple of Cardiff Oncology? | Current revenue multiple of Cardiff Oncology is 281.5x. |
| What is the current revenue growth of Cardiff Oncology? | Cardiff Oncology revenue growth between 2023 and 2024 was 40%. |
| Is Cardiff Oncology profitable? | Yes, Cardiff Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
